Biotechs fight fears of ‘antibiotic apocalypse’
Market failure gives little incentive to develop new drugs as antimicrobial resistance grows.
Carb-X and Repair Impact Fund to fund R&D of novel antibiotics. However, Pharma needs to take over later in the development.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.